AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Wave Life Sciences Ltd.

$4.59 -$11.36 (-71.22%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$4.67
Day Range
$4.56$4.72
Year Range
$4.56$21.73
Market Cap
904.45M
AVG Volume
3.35M
Trailing/Forward PE
-4.21/-
PEG ratio
-0.24
Dividend Yield
-
Next Earnings Date
2026-11-09
Primary Exchange
NASDAQUS
Revenue (USD)
-25M025M50M75M100M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q22.27M
26 Q138.25M
25 Q417.25M
25 Q37.61M
25 Q28.7M
25 Q19.18M
24 Q483.75M
24 Q3-7.68M
24 Q219.69M
24 Q112.54M
Net Income (USD)
-75M-50M-25M025M50M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-69.36M
26 Q1-26.09M
25 Q4-53.18M
25 Q3-53.85M
25 Q2-50.47M
25 Q1-46.88M
24 Q429.25M
24 Q3-61.78M
24 Q2-32.92M
24 Q1-31.56M
Operating Income (USD)
-75M-50M-25M025M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-73.8M
26 Q1-31.3M
25 Q4-56.47M
25 Q3-56.35M
25 Q2-52.76M
25 Q1-49.8M
24 Q422.97M
24 Q3-63.91M
24 Q2-35M
24 Q1-34.46M
EBITDA (USD)
-100M-50M050M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-71.22M
26 Q1-23.78M
25 Q4-50.92M
25 Q3-51.62M
25 Q2-48.27M
25 Q1-44.71M
24 Q431.41M
24 Q3-59.62M
24 Q2-30.75M
24 Q1-29.38M
Cash Flows (USD)
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-49.22M
26 Q1-59.99M
25 Q4-32.11M
25 Q3-44.91M
25 Q2-46.32M
25 Q1-63.2M
24 Q4-43.73M
24 Q3-46.86M
24 Q2-27.52M
24 Q1-33.85M
EPS (USD)
-0.6-0.4-0.2-00.224 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.34
26 Q1-0.13
25 Q4-0.3
25 Q3-0.32
25 Q2-0.31
25 Q1-0.29
24 Q40.17
24 Q3-0.47
24 Q2-0.25
24 Q1-0.24
Expenses (USD)
-20M020M40M60M80MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q276.96M
26 Q169.98M
25 Q473.7M
25 Q364.21M
25 Q261.76M
25 Q159.14M
24 Q460.87M
24 Q356.62M
24 Q254.74M
24 Q147.41M
Cash & Debt (USD)
0200M400M600M800MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q2490.6M
26 Q1544.59M
25 Q4602.07M
25 Q3196.22M
25 Q2208.48M
25 Q1243.07M
24 Q4302.08M
24 Q3310.95M
24 Q2153.96M
24 Q1180.92M
Debt ratios
0123424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Debt ratios by quarter
PeriodDebt ratios
26 Q22.26
26 Q13.03
25 Q42.99
25 Q31.56
25 Q21.54
25 Q12.12
24 Q43.13
24 Q32.12
24 Q21.92
24 Q12.78
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Margins by quarter
PeriodMargins
26 Q2100%
26 Q1100%
25 Q486.88%
25 Q3100%
25 Q274.76%
25 Q176.41%
24 Q4100%
24 Q3100%
24 Q2100%
24 Q1100%
Return on Capital
-800%-600%-400%-200%0%200%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Return on Capital by quarter
PeriodReturn on Capital
26 Q2-15.29%
26 Q1-5.1%
25 Q4-10.11%
25 Q3-43.24%
25 Q2-36.24%
25 Q1-27.29%
24 Q413.96%
24 Q3-41.32%
24 Q2-748.76%
24 Q1-124.3%
Shares Outstanding
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Shares Outstanding by quarter
PeriodShares Outstanding
26 Q2202.1M
26 Q1200.17M
25 Q4180.15M
25 Q3167.74M
25 Q2163.99M
25 Q1162.53M
24 Q4161.49M
24 Q3131.45M
24 Q2129.53M
24 Q1129.27M
Book Value Per Share (USD)
012324 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q22.24
26 Q12.56
25 Q42.92
25 Q30.74
25 Q20.85
25 Q11.06
24 Q41.3
24 Q31.14
24 Q20.03
24 Q10.2
Total Assets (USD)
0200M400M600M800M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
WVE Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q2558.32M
26 Q1583.54M
25 Q4638.5M
25 Q3241.38M
25 Q2252.35M
25 Q1288.34M
24 Q4352.21M
24 Q3358.5M
24 Q2208.82M
24 Q1235.27M
Employee Count
01002003004002016201720182019202020212022202320242025
WVE Employee Count by quarter
PeriodEmployee Count
2025317
2024287
2023266
2022250
2021235
2020217
2019301
2018250
2017168
201696
Free Cash Flow Yield
-25%-20%-15%-10%-5%med -13.87%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WVE Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-20.08%
Sep 26-18.96%
Aug 26-18.28%
Aug 26-17.42%
Aug 26-17.03%
Aug 26-15.11%
Jul 26-16.72%
Jul 26-15.76%
Jul 26-15.74%
Jul 26-14.65%
Jul 26-14.63%
Jun 26-15.71%
Jun 26-14.87%
Jun 26-15.6%
Jun 26-15.98%
May 26-13.92%
May 26-14.36%
May 26-13.53%
May 26-12.76%
May 26-12.51%
Apr 26-14.42%
Apr 26-13.83%
Apr 26-14.42%
Apr 26-14.22%
Mar 26-16.26%
Mar 26-8.81%
Mar 26-7.95%
Mar 26-7.89%
Feb 26-7.43%
Feb 26-8.76%
Feb 26-9.32%
Feb 26-8.78%
Jan 26-9.13%
Jan 26-8.77%
Jan 26-8.66%
Jan 26-8.54%
Jan 26-7.41%
Dec 25-6.65%
Dec 25-7.39%
Dec 25-7.13%
Dec 25-15.77%
Nov 25-15.22%
Nov 25-16.76%
Nov 25-16.69%
Nov 25-15.53%
Oct 25-13.5%
Oct 25-17.12%
Oct 25-15.63%
Oct 25-16.06%
Oct 25-17.07%
Sep 25-17.95%
Sep 25-17.71%
Sep 25-17.51%
Sep 25-14.72%
Aug 25-12.71%
Aug 25-12.02%
Aug 25-12.5%
Aug 25-15.08%
Aug 25-14.14%
Jul 25-13.28%
Jul 25-13.38%
Jul 25-14.49%
Jul 25-16.05%
Jun 25-16.73%
Jun 25-16.98%
Jun 25-16.05%
Jun 25-15.45%
May 25-18.56%
May 25-18.75%
May 25-17.62%
May 25-16.93%
May 25-11.62%
Apr 25-13.98%
Apr 25-15.9%
Apr 25-16.66%
Apr 25-15.61%
Mar 25-10.92%
Mar 25-9.81%
Mar 25-9.21%
Mar 25-10.01%
Feb 25-10.21%
Feb 25-9.69%
Feb 25-9.98%
Feb 25-9.66%
Jan 25-9.33%
Jan 25-8.98%
Jan 25-9.82%
Jan 25-9.35%
Jan 25-7.99%
Dec 24-8.36%
Dec 24-7.99%
Dec 24-8.03%
Dec 24-7.07%
Nov 24-7.15%
Nov 24-7.01%
Nov 24-7.32%
Nov 24-6.09%
Nov 24-7.24%
Oct 24-6.93%
Oct 24-6.54%
Price to Sales
0204060med 16.74Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WVE Price to Sales by quarter
PeriodPrice to Sales
Sep 2614.19
Sep 2615.03
Aug 2615.58
Aug 2616.35
Aug 2616.73
Aug 2618.86
Jul 2617.03
Jul 2616.2
Jul 2616.23
Jul 2617.42
Jul 2617.45
Jun 2616.25
Jun 2617.17
Jun 2616.37
Jun 2615.97
May 2618.34
May 2617.79
May 2618.87
May 2620.02
May 2620.41
Apr 2630.27
Apr 2631.58
Apr 2630.27
Apr 2630.7
Mar 2626.86
Mar 2649.58
Mar 2654.9
Mar 2655.32
Feb 2658.73
Feb 2620.72
Feb 2619.47
Feb 2620.65
Jan 2619.87
Jan 2620.69
Jan 2620.96
Jan 2621.25
Jan 2624.49
Dec 2527.29
Dec 2524.54
Dec 2525.43
Dec 2511.5
Nov 2511.92
Nov 2510.83
Nov 2510.87
Nov 2513.72
Oct 2515.78
Oct 2512.45
Oct 2513.63
Oct 2513.27
Oct 2512.48
Sep 2511.87
Sep 2512.03
Sep 2512.17
Sep 2514.47
Aug 2516.76
Aug 2517.72
Aug 2517.04
Aug 2514.12
Aug 2515.06
Jul 2513.01
Jul 2512.92
Jul 2511.93
Jul 2510.76
Jun 2510.33
Jun 2510.18
Jun 2510.76
Jun 2511.18
May 259.31
May 259.22
May 259.8
May 2510.21
May 2512.08
Apr 2510.04
Apr 258.83
Apr 258.42
Apr 258.99
Mar 2512.85
Mar 2514.3
Mar 2515.24
Mar 2514.02
Feb 2525.92
Feb 2527.29
Feb 2526.51
Feb 2527.39
Jan 2528.37
Jan 2529.45
Jan 2526.95
Jan 2528.3
Jan 2533.13
Dec 2431.63
Dec 2433.13
Dec 2432.95
Dec 2437.44
Nov 2437.02
Nov 2416.73
Nov 2416.02
Nov 2419.27
Nov 2416.21
Oct 2416.94
Oct 2417.95
Price to Book
0200400600med 7.98Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
WVE Price to Book by quarter
PeriodPrice to Book
Sep 262.05
Sep 262.17
Aug 262.25
Aug 262.36
Aug 262.41
Aug 262.72
Jul 262.46
Jul 262.27
Jul 262.28
Jul 262.44
Jul 262.45
Jun 262.28
Jun 262.41
Jun 262.3
Jun 262.24
May 262.57
May 262.5
May 262.65
May 262.81
May 262.86
Apr 262.46
Apr 262.56
Apr 262.46
Apr 262.49
Mar 262.18
Mar 264.03
Mar 264.46
Mar 264.49
Feb 264.77
Feb 2618.17
Feb 2617.08
Feb 2618.11
Jan 2617.43
Jan 2618.14
Jan 2618.38
Jan 2618.64
Jan 2621.48
Dec 2523.93
Dec 2521.52
Dec 2522.3
Dec 2510.09
Nov 2510.45
Nov 259.49
Nov 259.54
Nov 259.26
Oct 2510.64
Oct 258.4
Oct 259.2
Oct 258.95
Oct 258.42
Sep 258.01
Sep 258.11
Sep 258.21
Sep 259.76
Aug 2511.3
Aug 2511.95
Aug 2511.49
Aug 259.53
Aug 2510.16
Jul 257.95
Jul 257.89
Jul 257.28
Jul 256.57
Jun 256.31
Jun 256.22
Jun 256.57
Jun 256.83
May 255.69
May 255.63
May 255.99
May 256.23
May 256.24
Apr 255.19
Apr 254.56
Apr 254.35
Apr 254.65
Mar 256.64
Mar 257.39
Mar 257.88
Mar 257.25
Feb 259.29
Feb 259.79
Feb 259.5
Feb 259.82
Jan 2510.17
Jan 2510.56
Jan 259.66
Jan 2510.15
Jan 2511.88
Dec 2411.34
Dec 2411.88
Dec 2411.82
Dec 2413.42
Nov 2413.28
Nov 24420.37
Nov 24402.69
Nov 24484.29
Nov 24407.4
Oct 24425.67
Oct 24451
Wave Life Sciences Ltd.
WVE
Stockpicker

Video analysis: WVE

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: WVE

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

globenewswire.com · 3 Sep 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

247wallst.com · 13 Aug 2026

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

seekingalpha.com · 11 Aug 2026

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

globenewswire.com · 10 Aug 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

globenewswire.com · 5 Aug 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.

Wave Life Sciences to Present at Upcoming Investor Conferences

globenewswire.com · 4 Aug 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August.

WAVE Life Sciences Q2 Earnings Call Highlights

marketbeat.com · 30 Jul 2026

WAVE Life Sciences Q2 Earnings Call Highlights

WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

seekingalpha.com · 30 Jul 2026

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.